M Peyromaure
Overview
Explore the profile of M Peyromaure including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chakra M, Peyromaure M, Delongchamps N, Duquesne I
Acute Med
. 2022 Nov;
21(3):146.
PMID: 36427213
Misplacement of a urinary catheter in the ureter is a rare phenomenon. The described cases occurred in patients with neurogenic bladder. We describe an unusual case of 58 years old...
2.
Azoulai D, Boustany J, Peyromaure M, Chakra M, Duquesne I, Barry Delongchamps N
Prog Urol
. 2022 Aug;
32(16):1469-1475.
PMID: 35941010
Objectives: To determine the proportion of patients who would have been eligible for focal therapy (FT) in a population of patients who underwent prostatectomies; additionally, to assess the risk of...
3.
Chakra M, Roux S, Peyromaure M, Delongchamps N, Bailly H, Duquesne I
Ann R Coll Surg Engl
. 2022 May;
104(9):e258-e260.
PMID: 35639369
Penile Mondor's disease (PMD), or thrombosis of the dorsal vein, is an under-reported benign condition. Its aetiology is poorly understood. Clinically, it presents as a palpable cord in the dorsal...
4.
Coman R, Anract J, Pinar U, Sibony M, Peyromaure M, Delongchamps B
Int Urol Nephrol
. 2022 May;
54(7):1485-1489.
PMID: 35536389
Introduction: After most surgical management of benign prostatic hyperplasia (BPH), the resected tissue undergoes a histological examination. This examination is performed for the risk of finding an incidental prostate cancer...
5.
Abecassis J, Ghazzar N, Peyromaure M, Giraud P
Cancer Radiother
. 2020 Jul;
24(5):423-428.
PMID: 32620459
Prostate cancer is the most common malignant tumour and represents the third cause of cancer-mortality in men. The management of prostate cancer has dramatically changed over the last decades, mainly...
6.
Pinar U, Anract J, Duquesne I, Dariane C, Chartier-Kastler E, Cussenot O, et al.
Prog Urol
. 2020 May;
30(8-9):439-447.
PMID: 32430140
Introduction: As a result of the COVID-19 pandemic in France, all non-emergency surgical activity has been cancelled since March 12, 2020. In order to anticipate the reinstatement of delayed interventions,...
7.
Userovici M, Ochoa A, Anract J, Beurrier S, Peyromaure M, Barry Delongchamps N
Prog Urol
. 2020 Mar;
30(3):147-154.
PMID: 32127310
Introduction: Urolift® system is a mini-invasive technique, proposed as an alternative treatment for classic surgery of benign prostatic hyperplasia (BPH). Our objective was to report the results of Urolift® system...
8.
Anract J, Duquesne I, Montagne P, Sibony M, Beuvon F, Peyromaure M, et al.
Prog Urol
. 2019 Jun;
29(8-9):449-455.
PMID: 31230855
Introduction: The diagnosis of bladder urothelial tumors is based on bladder resection and histological analysis of the specimen. The time to obtain the results of the histological analysis increases the...
9.
Prin-Touvron L, Huillard O, Xylinas E, Orvoen G, Boudou-Rouquette P, Barry Delongchamps N, et al.
Prog Urol
. 2019 Jun;
29(6):318-325.
PMID: 31153857
Introduction: The incidence of cancer increases with age, especially for urological cancers. The frailty of the elderly persons may expose them to more postoperative complications resulting in prolonged hospitalization, increased...
10.
Anract J, Amouyal G, Peyromaure M, Zerbib M, Sapoval M, Barry Delongchamps N
Prog Urol
. 2019 Apr;
29(5):263-269.
PMID: 30948187
Introduction: Prostatic arterial embolization (PAE) is an experimental therapy for benign prostatic hyperplasia. Its feasibility is based on the knowledge of the pelvic arterial anatomy, and more specifically the prostate....